Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Chinese Patent Office
UBS
Baxter
Fish and Richardson
McKinsey

Generated: May 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,067,551

« Back to Dashboard

Which drugs does patent 7,067,551 protect, and when does it expire?

Patent 7,067,551 protects FARYDAK and is included in one NDA.

This patent has forty-six patent family members in thirty-three countries.

Summary for Patent: 7,067,551
Title:Deacetylase inhibitors
Abstract: The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
Inventor(s): Remiszewski; Stacy W (Washington Township, NJ), Bair; Kenneth W (Mountain Lakes, NJ), Versace; Richard W (Wanaque, NJ), Perez; Lawrence B (Hackettstown, NJ), Green; Michael A (Easton, PA), Sambucetti; Lidia C (Pacifica, CA), Sharma; Sushil (West Orange, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:10/984,501
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,067,551
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,067,551

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE ➤ Try a Free Trial
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-002 Feb 23, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE ➤ Try a Free Trial
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,067,551

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035057 ➤ Try a Free Trial
Austria 376999 ➤ Try a Free Trial
Australia 2001282129 ➤ Try a Free Trial
Australia 8212901 ➤ Try a Free Trial
Brazil 0113669 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Baxter
Argus Health
Chubb
Harvard Business School
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.